Blood Cancer Talks cover image

Episode 24. ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma

Blood Cancer Talks

00:00

The Importance of Comparative Efficacy in Early Relapse Patients

The real world data, I think, can also help us in this regard. Would you reserve CAR-T only for high-risk patients or those with aggressive relapse? It's a great question and one that I probably am still working through myself. And then once we get more survival data and more data on these non-relaps mortality, second malignancies, et cetera, if we're more comfortable that that's not eating in too much to the survival picture, there will be going to be using it for a lot more patients.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app